The 10 US Biosimilar Launches That Could Drive Big Savings By 2027

 
• By Jessica Merrill

Biosimilar versions of drugs like Humira, Stelara and Eylea are among the products that could generate cumulative sales of $129bn over the next five years, according to IQVIA.

Dice going up and down
The US is expected to spend more on biosimilars and save more on healthcare costs • Source: Shutterstock

More from Strategy

More from Business